BeiGene Strikes Deal for Global Rights to Ensem’s Phase 1-Ready Cancer Drug
BeiGene is expanding its cancer drug pipeline, landing global rights to an Ensem Therapeutics cancer drug candidate ready to enter the clinic. The drug targets CDK2, an enzyme whose excessive activity is associated with cancer progression.